PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

A recent retrospective study published in CHEST evaluated the effects of cystic fibrosis transmembrane conductance regulator ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...